Orgenesis INC 8-K filings

Orgenesis Inc. stockholders approved an amendment to increase authorized common stock from 14.58 million to 150 million shares.

Orgenesis Inc. announced the election of two new directors to its Board and the appointment of a new Chief Financial Officer, effective March 10, 2026.

Orgenesis Inc. has issued 3.29 million non-transferable warrants to Alpha Prosperity Fund SPC as part of a previously disclosed convertible loan agreement.

Orgenesis Inc. subsidiary Theracell Laboratories IKE secured a $1 million convertible loan and a $10 million credit facility, but faces significant potential equity dilution and loss of control.

Ashish Nanda has resigned from the Board of Directors of Orgenesis Inc., effective immediately, with no reported disagreements.

Orgenesis Inc. announced the immediate resignations of its Chief Financial Officer and three board directors, citing no disagreements with management.

Orgenesis Inc.'s common stock has been moved to the OTC Markets Expert Market tier due to a significant delay in filing its annual 10-K report.

Orgenesis Inc. has announced its common stock will be moved from OTCQX to the Pink Limited tier due to its failure to file its annual 10-K report for the period ending December 31, 2024.

Orgenesis Inc. received a notice from OTCQX regarding non-compliance due to the delayed filing of its 2024 Form 10-K and has until June 2, 2025, to rectify the situation or face delisting.

Orgenesis Inc. has acquired intellectual property assets related to spinal cord injury therapies from Neurocords, LLC in exchange for common stock and the termination of previous agreements.

Orgenesis has entered into an agreement for a $5 million equity investment from Williamsburg Venture Holdings to support the development of its decentralized cell and gene therapy platform.

Orgenesis Inc. will be delisted from the Nasdaq and a director has resigned, effective immediately.

Orgenesis Inc. is set to be delisted from the Nasdaq Stock Market and has entered into several loan and warrant agreements to secure short-term financing.

Orgenesis Inc. is set to be delisted from the Nasdaq Stock Market and has appointed three new members to its Board of Directors.

Orgenesis Inc. will be delisted from the Nasdaq Stock Market and has begun trading on the OTCQX market, while also experiencing a director's resignation.

Orgenesis Inc. has received notification from Nasdaq that its common stock will be delisted and trading will be suspended on October 21, 2024, with shares expected to move to the OTC Markets.

Orgenesis Inc. has announced a 1-for-10 reverse stock split to increase its share price and regain compliance with Nasdaq's minimum bid price requirement.

Orgenesis Inc. has released an investor presentation, which is included as an exhibit in a Form 8-K filing.

Orgenesis Maryland, a subsidiary of Orgenesis Inc., has entered into an amended and restated promissory note for $1 million with Jacob Safier, issuing warrants for common stock as partial consideration.

Orgenesis and Harley Street Healthcare Group have formed a joint venture to develop and commercialize wellness and longevity services, including personalized preventative care and regenerative therapies.

Orgenesis Inc. has entered into an agreement to acquire key assets from Theracell, including full ownership of Theracell Laboratories IKE and various cell therapy technologies, for a total consideration of $13 million.

Orgenesis Inc. has acquired CAR-T cell therapy processing technology from Broaden Bioscience for a maximum of $11 million, offset by existing debt, and secured an exclusive cell therapy processing agreement.

Orgenesis Inc. reports the resignation of director Curtis Slipman and the appointment of Dr. Itzhak Vider to the board, effective July 8, 2024.

Koligo Therapeutics, a subsidiary of Orgenesis Inc., has entered into a loan agreement for $2 million to support its working capital and operations.

Orgenesis Inc. held its 2024 annual meeting where stockholders approved an increase of 9,000,000 shares to the 2017 Equity Incentive Plan and elected five directors.

Orgenesis Inc. has been granted an extension until October 14, 2024, to regain compliance with Nasdaq listing requirements regarding bid price and equity.

Orgenesis Inc. has released an investor presentation, outlining its business strategy and future outlook.

Orgenesis Inc. has entered into agreements to exchange approximately $16 million in debt for over 15.7 million shares of common stock with three debt holders.

Orgenesis Inc. received a delisting notice from Nasdaq after restating its financials, revealing a stockholders' deficit and failing to meet minimum equity requirements.

Orgenesis Inc. announced it will restate its unaudited financial statements for the first three quarters of 2023 due to errors in revenue recognition and credit loss accounting.